adc-02265510

ADC-02265510 is a **selective agonist of the mu opioid receptor** with significantly higher affinity for the mu opioid receptor compared to delta or kappa receptors. It was evaluated for its ability to reduce dyskinesia severity in preclinical models of Parkinson's disease, specifically for L-DOPA-induced dyskinesia, an involuntary movement disorder common in advanced Parkinson's. ADC-02265510 demonstrated reduction in dyskinesia severity in MPTP-lesioned macaque monkeys both orally and via intracerebral administration, without affecting the antiparkinsonian activity of L-DOPA. The compound exhibits an EC50 of ~0.4 nM for human mu opioid receptor agonism.

Other names

adc-02265510adc02265510adc 02265510adc-5510adc5510adc 5510adl-5510adl5510adl 5510